.Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BA07_FoslevodopaAndDecarboxylaseInhib.FoslevodopaAndDecarboxylaseInhib .Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BA07_FoslevodopaAndDecarboxylaseInhib.FoslevodopaAndDecarboxylaseInhib| name: | FoslevodopaAndDecarboxylaseInhibitor |
| ATC code: | N04BA07 | route: | intravenous |
| n-compartments | 2 |
Foslevodopa is a phosphate prodrug of levodopa developed to provide continuous dopaminergic stimulation for the management of Parkinson's disease, co-administered with a decarboxylase inhibitor to reduce peripheral levodopa metabolism. The drug is under clinical development and not yet generally approved for clinical use.
No published pharmacokinetic data available for foslevodopa and decarboxylase inhibitor combination in humans. Parameters below are not experimentally determined but estimated based on general properties of levodopa prodrugs and intravenous/oral levodopa administration.